Trade Harvard Bioscience - HBIO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.1910 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Harvard Bioscience Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 4.3795 |
| Open* | 4.4095 |
| 1-Year Change* | 54.38% |
| Day's Range* | 4.3695 - 4.4095 |
| 52 wk Range | 1.98-6.29 |
| Average Volume (10 days) | 69.60K |
| Average Volume (3 months) | 1.94M |
| Market Cap | 180.14M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 42.69M |
| Revenue | 112.52M |
| EPS | -0.08 |
| Dividend (Yield %) | N/A |
| Beta | 1.46 |
| Next Earnings Date | Mar 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 1, 2023 | 4.3795 | 0.1700 | 4.04% | 4.2095 | 4.3795 | 4.2095 |
| Nov 30, 2023 | 4.2395 | 0.0000 | 0.00% | 4.2395 | 4.3295 | 4.2095 |
| Nov 29, 2023 | 4.3095 | 0.0700 | 1.65% | 4.2395 | 4.3595 | 4.2395 |
| Nov 28, 2023 | 4.2795 | -0.1300 | -2.95% | 4.4095 | 4.4095 | 4.2395 |
| Nov 27, 2023 | 4.4295 | -0.1000 | -2.21% | 4.5295 | 4.6495 | 4.4295 |
| Nov 24, 2023 | 4.5895 | 0.3000 | 6.99% | 4.2895 | 4.6695 | 4.2895 |
| Nov 22, 2023 | 4.3295 | 0.2200 | 5.35% | 4.1095 | 4.4395 | 4.1095 |
| Nov 21, 2023 | 4.1995 | 0.0300 | 0.72% | 4.1695 | 4.3095 | 4.0395 |
| Nov 20, 2023 | 4.1995 | -0.0600 | -1.41% | 4.2595 | 4.2595 | 4.1295 |
| Nov 17, 2023 | 4.2395 | 0.1300 | 3.16% | 4.1095 | 4.2795 | 4.1095 |
| Nov 16, 2023 | 4.2195 | 0.0500 | 1.20% | 4.1695 | 4.2795 | 4.0895 |
| Nov 15, 2023 | 4.2395 | 0.0700 | 1.68% | 4.1695 | 4.4295 | 4.1695 |
| Nov 14, 2023 | 4.3195 | 0.3300 | 8.27% | 3.9895 | 4.3595 | 3.9895 |
| Nov 13, 2023 | 4.0795 | 0.2300 | 5.97% | 3.8495 | 4.1495 | 3.8495 |
| Nov 10, 2023 | 3.9895 | -0.0500 | -1.24% | 4.0395 | 4.0695 | 3.6795 |
| Nov 9, 2023 | 4.0695 | 0.0000 | 0.00% | 4.0695 | 4.2195 | 4.0395 |
| Nov 8, 2023 | 4.1395 | 0.0000 | 0.00% | 4.1395 | 4.1595 | 3.9895 |
| Nov 7, 2023 | 4.2395 | 0.0500 | 1.19% | 4.1895 | 4.4295 | 4.1895 |
| Nov 6, 2023 | 4.2695 | 0.0300 | 0.71% | 4.2395 | 4.2895 | 4.1795 |
| Nov 3, 2023 | 4.2795 | 0.0000 | 0.00% | 4.2795 | 4.4295 | 4.2095 |
Harvard Bioscience Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, March 7, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Q4 2023 Harvard Bioscience Inc Earnings Release Q4 2023 Harvard Bioscience Inc Earnings ReleaseForecast -Previous - |
| Tuesday, April 23, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q1 2024 Harvard Bioscience Inc Earnings Release Q1 2024 Harvard Bioscience Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 113.335 | 118.904 | 102.1 | 116.176 | 120.774 |
| Revenue | 113.335 | 118.904 | 102.1 | 116.176 | 120.774 |
| Cost of Revenue, Total | 51.045 | 51.252 | 44.059 | 51.654 | 53.793 |
| Gross Profit | 62.29 | 67.652 | 58.041 | 64.522 | 66.981 |
| Total Operating Expense | 120.268 | 116.838 | 103.755 | 115.799 | 123.19 |
| Selling/General/Admin. Expenses, Total | 48.611 | 47.672 | 43.425 | 45.324 | 45.825 |
| Research & Development | 12.329 | 10.799 | 8.685 | 10.715 | 10.988 |
| Depreciation / Amortization | 6.122 | 5.84 | 5.71 | 5.746 | 5.384 |
| Unusual Expense (Income) | 2.161 | 1.275 | 1.876 | 2.36 | 7.2 |
| Operating Income | -6.933 | 2.066 | -1.655 | 0.377 | -2.416 |
| Interest Income (Expense), Net Non-Operating | -2.548 | -1.54 | -4.831 | -5.41 | -5.219 |
| Other, Net | 0.302 | -0.666 | -0.806 | -0.469 | -0.34 |
| Net Income Before Taxes | -9.179 | -0.14 | -7.292 | -5.502 | -7.975 |
| Net Income After Taxes | -9.516 | -0.288 | -7.81 | -4.687 | -4.299 |
| Net Income Before Extra. Items | -9.516 | -0.288 | -7.81 | -4.687 | -4.299 |
| Net Income | -9.516 | -0.288 | -7.81 | -4.687 | -2.922 |
| Income Available to Common Excl. Extra. Items | -9.516 | -0.288 | -7.81 | -4.687 | -4.299 |
| Income Available to Common Incl. Extra. Items | -9.516 | -0.288 | -7.81 | -4.687 | -2.922 |
| Diluted Net Income | -9.516 | -0.288 | -7.81 | -4.687 | -2.922 |
| Diluted Weighted Average Shares | 41.413 | 40.343 | 38.64 | 37.814 | 36.453 |
| Diluted EPS Excluding Extraordinary Items | -0.22978 | -0.00714 | -0.20212 | -0.12395 | -0.11793 |
| Diluted Normalized EPS | -0.19586 | 0.0134 | -0.13637 | -0.08338 | 0.01045 |
| Total Extraordinary Items | 0 | 1.377 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 28.759 | 29.975 | 28.427 | 26.922 | 29.208 |
| Revenue | 28.759 | 29.975 | 28.427 | 26.922 | 29.208 |
| Cost of Revenue, Total | 12.086 | 11.629 | 12.594 | 14.75 | 12.571 |
| Gross Profit | 16.673 | 18.346 | 15.833 | 12.172 | 16.637 |
| Total Operating Expense | 27.963 | 28.226 | 28.884 | 30.684 | 25.21 |
| Selling/General/Admin. Expenses, Total | 11.531 | 12.312 | 11.811 | 12.143 | 12.568 |
| Research & Development | 2.957 | 2.897 | 2.849 | 2.763 | 3.497 |
| Depreciation / Amortization | 1.389 | 1.388 | 1.63 | 1.572 | 1.454 |
| Unusual Expense (Income) | 0 | 0 | 0 | -0.544 | -4.88 |
| Operating Income | 0.796 | 1.749 | -0.457 | -3.762 | 3.998 |
| Interest Income (Expense), Net Non-Operating | -2.522 | -0.974 | -0.9 | -0.749 | -0.515 |
| Other, Net | -0.372 | 0.432 | 0.465 | -0.179 | -0.062 |
| Net Income Before Taxes | -2.098 | 1.207 | -0.892 | -4.69 | 3.421 |
| Net Income After Taxes | -0.98 | 0.622 | -1.666 | -3.405 | 2.435 |
| Net Income Before Extra. Items | -0.98 | 0.622 | -1.666 | -3.405 | 2.435 |
| Net Income | -0.98 | 0.622 | -1.666 | -3.405 | 2.435 |
| Income Available to Common Excl. Extra. Items | -0.98 | 0.622 | -1.666 | -3.405 | 2.435 |
| Income Available to Common Incl. Extra. Items | -0.98 | 0.622 | -1.666 | -3.405 | 2.435 |
| Diluted Net Income | -0.98 | 0.622 | -1.666 | -3.405 | 2.435 |
| Diluted Weighted Average Shares | 42.354 | 42.783 | 41.593 | 41.637 | 42.56 |
| Diluted EPS Excluding Extraordinary Items | -0.02314 | 0.01454 | -0.04005 | -0.08178 | 0.05721 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.02314 | 0.01454 | -0.04005 | -0.09027 | -0.01732 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 51.124 | 61.583 | 51.7 | 53.572 | 57.832 |
| Cash and Short Term Investments | 4.508 | 7.821 | 8.317 | 8.335 | 8.173 |
| Cash & Equivalents | 4.508 | 7.821 | 8.317 | 8.335 | 8.173 |
| Total Receivables, Net | 20.177 | 26.175 | 21.121 | 23.176 | 24.572 |
| Accounts Receivable - Trade, Net | 16.705 | 21.834 | 17.766 | 20.704 | 21.463 |
| Total Inventory | 26.439 | 27.587 | 22.262 | 22.061 | 25.087 |
| Other Current Assets, Total | |||||
| Total Assets | 145.36 | 162.344 | 156.254 | 164.87 | 168.613 |
| Property/Plant/Equipment, Total - Net | 9.182 | 10.312 | 11.721 | 13.239 | 5.898 |
| Property/Plant/Equipment, Total - Gross | 24.028 | 24.761 | 28.318 | 28.179 | 23.336 |
| Accumulated Depreciation, Total | -14.846 | -14.449 | -16.597 | -14.94 | -17.438 |
| Goodwill, Net | 56.26 | 57.689 | 58.59 | 57.381 | 57.304 |
| Intangibles, Net | 21.014 | 27.385 | 33.151 | 38.405 | 45.764 |
| Other Long Term Assets, Total | 7.78 | 5.375 | 1.092 | 2.273 | 1.815 |
| Total Current Liabilities | 23.249 | 25.316 | 21.053 | 25.312 | 25.489 |
| Accounts Payable | 6.447 | 4.911 | 5.972 | 5.339 | 7.359 |
| Accrued Expenses | 8.639 | 11.175 | 7.582 | 2.424 | 5.762 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 3.811 | 3.235 | 1.721 | 6.9 | 5.982 |
| Other Current Liabilities, Total | 4.352 | 5.995 | 5.778 | 10.649 | 6.386 |
| Total Liabilities | 73.14 | 78.943 | 79.573 | 83.176 | 85.889 |
| Total Long Term Debt | 43.013 | 45.095 | 46.286 | 46.917 | 54.813 |
| Long Term Debt | 43.013 | 45.095 | 46.286 | 46.917 | 54.813 |
| Deferred Income Tax | 0.59 | 1.558 | 1.899 | 1.974 | 2.301 |
| Other Liabilities, Total | 6.288 | 6.974 | 10.335 | 8.973 | 3.286 |
| Total Equity | 72.22 | 83.401 | 76.681 | 81.694 | 82.724 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.454 | 0.452 | 0.444 | 0.438 | 0.436 |
| Additional Paid-In Capital | 229.008 | 225.65 | 232.357 | 229.189 | 226.377 |
| Retained Earnings (Accumulated Deficit) | -142.19 | -132.674 | -132.386 | -124.576 | -119.889 |
| Treasury Stock - Common | 0 | -10.668 | -10.668 | -10.668 | |
| Other Equity, Total | -15.052 | -10.027 | -13.066 | -12.689 | -13.532 |
| Total Liabilities & Shareholders’ Equity | 145.36 | 162.344 | 156.254 | 164.87 | 168.613 |
| Total Common Shares Outstanding | 42.0817 | 41.1429 | 39.4071 | 38.1882 | 37.3788 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 50.486 | 52.617 | 52.449 | 51.124 | 51.818 |
| Cash and Short Term Investments | 5.34 | 4.324 | 3.789 | 4.508 | 5.144 |
| Cash & Equivalents | 5.34 | 4.324 | 3.789 | 4.508 | 5.144 |
| Total Receivables, Net | 19.328 | 22.204 | 21.799 | 20.177 | 20.558 |
| Accounts Receivable - Trade, Net | 14.983 | 16.903 | 17.737 | 16.705 | 15.023 |
| Total Inventory | 25.818 | 26.089 | 26.861 | 26.439 | 26.116 |
| Total Assets | 139.735 | 142.899 | 145.578 | 145.36 | 147.013 |
| Property/Plant/Equipment, Total - Net | 8.419 | 8.744 | 8.929 | 9.182 | 9.574 |
| Goodwill, Net | 56.222 | 56.771 | 56.618 | 56.26 | 54.851 |
| Intangibles, Net | 17.095 | 18.356 | 19.641 | 21.014 | 22.464 |
| Other Long Term Assets, Total | 7.513 | 6.411 | 7.941 | 7.78 | 8.306 |
| Total Current Liabilities | 24.205 | 22.942 | 23.217 | 23.249 | 21.36 |
| Accounts Payable | 6.269 | 4.716 | 5.978 | 6.447 | 5.877 |
| Accrued Expenses | 9.516 | 9.438 | 8.356 | 8.639 | 8.165 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 3.47 | 3.22 | 2.97 | 3.811 | 2.72 |
| Other Current Liabilities, Total | 4.95 | 5.568 | 5.913 | 4.352 | 4.598 |
| Total Liabilities | 65.449 | 67.511 | 71.238 | 73.14 | 75.034 |
| Total Long Term Debt | 35.273 | 38.203 | 41.083 | 43.013 | 46.534 |
| Long Term Debt | 35.273 | 38.203 | 41.083 | 43.013 | 46.534 |
| Deferred Income Tax | 0.661 | 0.667 | 0.546 | 0.59 | 1.181 |
| Other Liabilities, Total | 5.31 | 5.699 | 6.392 | 6.288 | 5.959 |
| Total Equity | 74.286 | 75.388 | 74.34 | 72.22 | 71.979 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.457 | 0.457 | 0.455 | 0.454 | 0.453 |
| Additional Paid-In Capital | 232.896 | 231.533 | 230.108 | 229.008 | 228.229 |
| Retained Earnings (Accumulated Deficit) | -143.787 | -142.548 | -141.568 | -142.19 | -140.524 |
| Treasury Stock - Common | |||||
| Other Equity, Total | -15.28 | -14.054 | -14.655 | -15.052 | -16.179 |
| Total Liabilities & Shareholders’ Equity | 139.735 | 142.899 | 145.578 | 145.36 | 147.013 |
| Total Common Shares Outstanding | 42.6883 | 42.6883 | 42.19 | 42.0817 | 41.6577 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -9.516 | -0.288 | -7.81 | -4.687 | -2.922 |
| Cash From Operating Activities | 1.152 | 1.262 | 9.331 | 8.045 | 2.884 |
| Cash From Operating Activities | 1.453 | 1.781 | 1.922 | 1.987 | 2.423 |
| Amortization | 6.122 | 5.84 | 5.71 | 5.746 | 5.459 |
| Deferred Taxes | -0.414 | -0.33 | -0.143 | -0.398 | -2.861 |
| Non-Cash Items | 0.791 | 4.449 | 5.546 | 5.355 | 2.46 |
| Cash Taxes Paid | 0.534 | 0.577 | 0.416 | 0.374 | -0.098 |
| Cash Interest Paid | 2.314 | 1.577 | 4.881 | 5.496 | 4.987 |
| Changes in Working Capital | 2.716 | -10.19 | 4.106 | 0.042 | -1.675 |
| Cash From Investing Activities | -1.59 | -1.345 | -1.402 | -0.229 | -53.796 |
| Capital Expenditures | -1.59 | -1.345 | -1.152 | -1.216 | -1.006 |
| Other Investing Cash Flow Items, Total | -0.25 | 0.987 | -52.79 | ||
| Cash From Financing Activities | -2.837 | -0.252 | -7.967 | -7.624 | 53.053 |
| Issuance (Retirement) of Stock, Net | 0.577 | 3.314 | 4.557 | ||
| Issuance (Retirement) of Debt, Net | -1.786 | 0.05 | -5.597 | -7.403 | 48.496 |
| Foreign Exchange Effects | -0.038 | -0.161 | 0.02 | -0.03 | 0.299 |
| Net Change in Cash | -3.313 | -0.496 | -0.018 | 0.162 | 2.44 |
| Financing Cash Flow Items | -1.628 | -3.616 | -2.37 | -0.221 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 0.622 | -9.516 | -7.85 | -4.445 | -6.88 |
| Cash From Operating Activities | 1.812 | 1.152 | -1.527 | -2.176 | -1.986 |
| Cash From Operating Activities | 0.333 | 1.453 | 1.122 | 0.758 | 0.382 |
| Amortization | 1.388 | 6.122 | 4.492 | 2.92 | 1.466 |
| Non-Cash Items | 0.765 | 0.791 | -0.289 | -1.498 | 0.97 |
| Cash Taxes Paid | -0.134 | 0.534 | 0.493 | 0.352 | 0.107 |
| Cash Interest Paid | 1.172 | 2.314 | 1.529 | 0.845 | 0.383 |
| Changes in Working Capital | -1.296 | 2.716 | 1.158 | -0.951 | 2.076 |
| Cash From Investing Activities | 0.288 | -1.59 | -1.355 | -0.913 | -0.471 |
| Capital Expenditures | -0.224 | -1.59 | -1.355 | -0.913 | -0.471 |
| Cash From Financing Activities | -2.893 | -2.837 | -0.107 | -0.484 | 0.094 |
| Financing Cash Flow Items | -0.156 | -1.628 | -1.167 | -0.78 | -0.501 |
| Issuance (Retirement) of Stock, Net | 0.104 | 0.577 | 0.346 | 0.282 | 0.031 |
| Issuance (Retirement) of Debt, Net | -2.841 | -1.786 | 0.714 | 0.014 | 0.564 |
| Foreign Exchange Effects | 0.074 | -0.038 | 0.312 | 0.011 | -0.025 |
| Net Change in Cash | -0.719 | -3.313 | -2.677 | -3.562 | -2.388 |
| Deferred Taxes | -0.414 | -0.16 | 1.04 | ||
| Other Investing Cash Flow Items, Total | 0.512 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| B. Riley Asset Management, LLC | Investment Advisor/Hedge Fund | 7.1752 | 3062963 | -345833 | 2023-06-30 | MED |
| Punch & Associates Investment Management, Inc. | Investment Advisor/Hedge Fund | 6.8474 | 2923034 | 60385 | 2023-09-30 | LOW |
| Harvey Partners, LLC | Hedge Fund | 5.9126 | 2524000 | -188700 | 2023-06-30 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.6404 | 2407796 | 1544721 | 2023-06-30 | LOW |
| AMH Equity, Ltd. | Hedge Fund | 4.7773 | 2039328 | 39328 | 2023-08-25 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.5962 | 1962017 | 218021 | 2023-06-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 4.2579 | 1817629 | 72496 | 2023-06-30 | LOW |
| Green (James W) | Individual Investor | 3.5248 | 1504694 | 25000 | 2023-08-17 | MED |
| Granahan Investment Management, Inc. | Investment Advisor | 3.372 | 1439450 | 9299 | 2023-06-30 | LOW |
| Royce Investment Partners | Investment Advisor/Hedge Fund | 3.2815 | 1400829 | -38353 | 2023-06-30 | LOW |
| Boothbay Fund Management, LLC | Investment Advisor/Hedge Fund | 2.7508 | 1174247 | -60851 | 2023-06-30 | HIGH |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 2.5891 | 1105253 | 0 | 2023-06-30 | MED |
| Heartland Advisors, Inc. | Investment Advisor/Hedge Fund | 1.9912 | 850000 | -350000 | 2023-06-30 | |
| Meros Investment Management, LP | Investment Advisor | 1.9045 | 813014 | -311192 | 2023-06-30 | MED |
| Portolan Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8356 | 783591 | -259955 | 2023-06-30 | HIGH |
| Renaissance Technologies LLC | Hedge Fund | 1.7621 | 752207 | 22200 | 2023-06-30 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6977 | 724729 | 385706 | 2023-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.4685 | 626880 | 499328 | 2023-06-30 | LOW |
| Monarch Partners Asset Management LLC | Investment Advisor/Hedge Fund | 1.438 | 613837 | -187422 | 2022-12-31 | |
| Loy (Bertrand) | Individual Investor | 1.1704 | 499633 | 31516 | 2023-05-22 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Harvard Bioscience Company profile
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a developer, manufacturer, and seller of technologies, products and services that enable fundamental research, discovery, and preclinical testing for drug development. The Company provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms, and clinical. The Company primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The Company’s customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Harvard Bioscience, Inc. revenues increased 16% to $118.9M. Net loss decreased 96% to $288K. Revenues reflect United States segment increase of 18% to $49.8M, Europe segment increase of 19% to $35.8M. Lower net loss reflects Interest expense decrease of 68% to $1.5M (expense), G/L on early Exting of lease relat debt decrease from $1.9M (expense) to $0K.
Equity composition
Common Stock $.01 Par, 12/10, 80M auth., 36,057,974 issd., less 7,745,507 shs. in Treas. @ 10.7M. Insiders & Strategic holders own 13.56%. IPO: 12/7/2000, 6,420,000 shs. @$8 by Thomas Weisel Partners LLC. *NOTE: 10/02, Company acquired Genomic Solutions, Inc. @ 0.1017 shares and $0.286 in cash (3,178,857 shares issd.).
| Industry: | Advanced Medical Equipment & Technology (NEC) |
84 October Hill Rd
HOLLISTON
MASSACHUSETTS 01746-1371
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com